COG NCTN Network Group Operations Center - Year 10 STAR Act COG) Outcomes & Survivorship (LTE) Committee

COG NCTN 网络集团运营中心 - 第 10 年 STAR 法案 COG) 结果

• 批准号: 10918928
• 负责人: Douglas S. Hawkins
• 金额: $ 324.3万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10918928
• 关键词: 1 year old; Acceleration; Acute; Acute Myelocytic Leukemia; Adolescent; Australia; Brain Stem Glioma; Canada; Cancer Center; Cancer Patient; Caring; Cause of Death; Cell Therapy; Child; Child Support; Childhood; Childhood Leukemia; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Collection; Communities; Complication; Country; Development; Diagnosis; Disease; Dose; Eligibility Determination; Enrollment; Ensure; Family; Foundations; Functional disorder; Generations; Goals; Hormonal; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; Knowledge; Laboratories; Late Effects; Lead; Malignant Childhood Neoplasm; Malignant Neoplasms; Methods; Mission; Molecular; Morbidity - disease rate; National Cancer Institute; National Clinical Trials Network; Neuroblastoma; New Zealand; Organ; Outcome; Patients; Pediatric Hospitals; Pediatric Oncology Group; Pharmaceutical Preparations; Population Heterogeneity; Population Research; Positioning Attribute; Productivity; Prognosis; Quality of life; Rare Diseases; Research; Research Personnel; Scientist; Second Primary Cancers; Site; Survival Rate; Survivors; Tissues; Translational Research; United States; Universities; Work; anticancer research; cancer diagnosis; cancer therapy; chemotherapy; childhood cancer survivor; clinical translation; design; experience; health related quality of life; high risk; improved; improved outcome; innovation; member; multidisciplinary; novel therapeutic intervention; operation; organizational structure; reproductive; small molecule; success; survivorship; translational study

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

项目摘要 自从60多年前引入化疗治疗儿童白血病以来， 儿童癌症的预后已显著改善。儿童癌症的总体5年生存率， 其中许多在化疗前是致命的，现在是84%。一些儿童的进步 然而，癌症的治疗是有限的，大约50%的儿童患有急性骨髓性白血病，50% 的高危神经母细胞瘤儿童，以及超过90%的脑干胶质瘤儿童， 他们的疾病。在美国，癌症仍然是一岁以上儿童疾病死亡的主要原因。 年龄。此外，癌症治疗的晚期效应，包括永久性器官和组织损伤， 荷尔蒙和生殖功能障碍以及第二种癌症，特别令人关注， 500，000名儿童癌症幸存者（估计截至2020年）经历了显著的健康相关质量， 儿童癌症的生活并发症及其治疗因此，尽管我们的进步，新的发展， 治疗方法必须是儿童癌症基础、转化和临床研究人员的优先事项。的 儿童肿瘤学小组（COG）是世界上最大的专门致力于儿童和 青少年癌症研究中心成立于20年前。COG的多学科研究团队，包括 该组织拥有9,000多名成员，在220多家领先的儿童医院、大学和 癌症中心该提案是针对COG的，作为国家癌症研究所（NCI）国家临床试验的一部分 网络（NCTN），继续其合作研究工作，支持改善成果的使命 为所有患有癌症的儿童提供帮助。COG将为癌症儿童设计和开展临床转化研究 该研究建立在对儿科恶性肿瘤分子基础的日益了解的基础上， 改善结果的潜力。采用适合罕见病研究的创新临床试验设计， 我们将研究新的治疗方法，包括但不限于靶向小分子药物， 免疫疗法和细胞疗法。重要的是，COG的研究组合还包括临床试验 重点是提高癌症儿童和儿童癌症幸存者的生活质量。余 在美国，90%被诊断患有癌症的儿童在COG成员机构接受治疗，COG有能力 为不同的癌症儿童及其家人提供参与创新的 research.这项研究工作包括允许收集和注释所有儿童的生物标本 与癌症，提供基础的发现和加速最有前途的研究工作 在世界各地的实验室进行。该提案是为了支持COG网络运营中心， 开发和开展研究的临床医生-科学家，成员研究中心通过招募 合格受试者。